Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) CRH Antibodies:
anti-Human CRH Antibodies:
anti-Rat (Rattus) CRH Antibodies:
Go to our pre-filtered search.
Mouse (Murine) Polyclonal CRH Primary Antibody for IEM, ICC - ABIN617894
Preeyasombat, Sirikulchayanonta, Mahachokelertwattana, Sriphrapradang, Boonpucknavig: Cushing's syndrome caused by Ewing's sarcoma secreting corticotropin releasing factor-like peptide. in American journal of diseases of children (1960) 1992
Show all 22 Pubmed References
Human Monoclonal CRH Primary Antibody for ELISA, WB - ABIN514593
Wang, Parobchak, Rosen: RelB/NF-?B2 regulates corticotropin-releasing hormone in the human placenta. in Molecular endocrinology (Baltimore, Md.) 2012
Show all 3 Pubmed References
Human Polyclonal CRH Primary Antibody for ICC, IF - ABIN259726
El Yamani, Yon, Guérin, El Ouezzani, Alaoui, Chartrel, Anouar, Magoul et al.: Immunocytochemical distribution of EM66 within the hypothalamic parvocellular paraventricular nucleus: colocalization with CRH and TRH but no plasticity related to acute stress and thyroidectomy in ... in Regulatory peptides 2013
Show all 2 Pubmed References
Human Polyclonal CRH Primary Antibody for IF (p), IHC (p) - ABIN726800
Balan, Warnock, Puche, Gondre-Lewis, Aurelian: Innately activated TLR4 signal in the nucleus accumbens is sustained by CRF amplification loop and regulates impulsivity. in Brain, behavior, and immunity 2017
Hypothalamic CRH-expressing neurons orchestrate complex behaviors after stress.
Mice lacking corticotropin-releasing hormone, had an improved ability to escape away from potentially dangerous situations.
our results suggest an inhibitory role of miR (show MLXIP Antibodies)-212 on the HPA (show HPSE Antibodies) axis, which acts in a counter-regulatory manner.
Study shows that prolactin (show PRL Antibodies) was sufficient to suppress corticotrophin-releasing hormone (CRH) mRNA expression in the paraventricular nucleus, however it does not appear to be required for the ongoing regulation of the CRH neurones in lactation.
Study blocked endogenous CRH using 2 chemically distinct antagonists of the principal hippocampal CRH receptor, CRHR1 (show CRHR1 Antibodies). The antagonists caused a modest reduction of spontaneous excitatory transmission onto CA3 (show CA3 Antibodies) pyramidal cells, mediated. This was accompanied by a decrease in incidence but not amplitude of sharp waves, indicating that CRH synaptic actions are sufficient to alter the output of a complex hippocampal network.
Mice exposed to aggressive confrontations exhibited a similar pattern of species-typical aggressive and non-aggressive behaviors on the first and the last session. Repeated aggressive confrontations promoted an increase in plasma corticosterone. After 10 aggressive confrontation sessions, mice presented a non-significant trend toward reducing hippocampal levels of CRF, which inversely correlated with plasma corticosterone
Data (including data from studies in transgenic mice) suggest that Crh alters Gnrh neuron activity and that estradiol is required for Crh to exert both stimulatory and inhibitory effects on Gnrh neurons. (Crh = corticotropin-releasing hormone; Gnrh = gonadotropin releasing hormone)
The activation of parvalbumin (show PVALB Antibodies)(+) interneurons during morphine withdrawal was crucial for the induction of the negative emotion and the up-regulation of CRH mRNA levels in the central amygdala.
Psychological stress-derived CRF can breach the established endotoxin tolerance in the intestinal mucosa.
CRF plays a marked anxiogenic role at CRF1 receptors in the amygdala of mice exposed to the Elevated plus maze.
Significant effects of CNS sensitization on CRF mRNA levels were detected in the Dorsal Striatum (increasing effect).
These results show epigenetic changes in the CRH gene related to severity of suicide attempt in adults and a general psychiatric risk score in adolescents.
Data suggest that corticotrophin-releasing hormone (CRH) is able to stimulate copeptin (show AVP Antibodies) release in healthy controls suggesting direct interaction of CRH/CRH-receptor signaling and vasopressin (show AVP Antibodies); these interactions appear to be altered in patients with pituitary disease; copeptin (show AVP Antibodies) may be serum biomarker of altered CRH/CRH-receptor signaling in pituitary diseases.
The development of disorders related to heightened stress sensitivity and dysregulation of stress-coping mechanisms appears to involve regulatory mechanisms of the CRH family members. The purpose of this review is to summarize the most significant discoveries related to CRH over time. [review]
A significant increase in CRH and CRHR-1 (show CRHR1 Antibodies) expression was significantly correlated with psychological stress in vitiligo (show MITF Antibodies).
Corticotrophin-releasing hormone accelerated tumor angiogenesis by upregulating VEGF (show VEGFA Antibodies) expression and secretion in colon cancer cells.
This study found that the expressions of CRH and CRHR1 (show CRHR1 Antibodies) were significantly higher in the epileptogenic tissues of patients with IS than in the control group.
The authors propose that conditions impacting on epiallele distribution influence the number of transcriptionally active CRH gene copies in the trophoblast cell population determining the gestational trajectory of placental CRH production in normal and pathological pregnancies.
Neuroimmune-endocrine events may lead to overactivity of sympathetic nervous system that triggers cascade of pathologic conditions in ovary in polycystic ovary syndrome (PCOS). Data suggest that women with PCOS exhibit reduction of CRH and NGF (show NGFB Antibodies); reduction of CRH and NGF (show NGFB Antibodies) may be under influence of sympathetic nervous system and may reflect deficit of neuronal stress-adaptation in PCOS patients. (NGF (show NGFB Antibodies) = nerve growth factor)
brain activation in response to colorectal distention is enhanced after CRH injection in Irritable bowel syndrome patients compared to healthy controls
Evidence is provided for porcine corticotropin releasing hormone (CRH) as a quantitative trait locus (QTL) affecting growth and body composition. (corticotropin releasing hormone; CRH; CRF)
CRH inhibits local progesterone production from luteal cells in swine corpus lutem.
CRF-mediated cytoprotection occurs through the slow and tightly controlled apoptotic pathway.
We show that the CRF system is expressed in fish heart, is upregulated by hypoxia, and is cytoprotective.
Rigorous acute stressor stimuli induce behavioral changes, accompanied by an increase of cortisol levels with delayed control of CRH mRNA expression.
CRF localized in the preoptic area, periventricular hypothalamic and tectal regions, and dorsal part of the trigeminal motor nucleus.
The results of this study indicated that chronic CRF overexpression in primates not only increases Anxious Temperament but also affects metabolism and connectivity within components of Anxious Temperament 's neural circuitry.
We show that -2232C>G alters DNA x protein interactions and confers decreased sensitivity of the CRH promoter to glucocorticoids in vitro.
Data suggest that CRH promoter variation that confers increased stress reactivity increases the risk for alcohol use disorders in stress-exposed individuals.
The association has been reported between polymorphisms of the CRH and POMC (show POMC Antibodies) genes with economic traits in Korean cattle.
CRH is a promising candidate gene for a concordant QTL related to lipid metabolism in mammals.
corticotropin-releasing factor mRNA fluctuated with food intake in the hypothalamus, pretectum, and optic tectum; CRF mRNA decreased 6 h after a meal and remained low through 31 days of food deprivation
Corticotropin-releasing hormone is secreted by the paraventricular nucleus (PVN) of the hypothalamus in response to stress. Marked reduction in this protein has been observed in association with Alzheimer disease and autosomal recessive hypothalamic corticotropin deficiency has multiple and potentially fatal metabolic consequences including hypoglycemia and hepatitis. In addition to production in the hypothalamus, this protein is also synthesized in peripheral tissues, such as T lymphocytes and is highly expressed in the placenta. In the placenta it is a marker that determines the length of gestation and the timing of parturition and delivery. A rapid increase in circulating levels of the hormone occurs at the onset of parturition, suggesting that, in addition to its metabolic functions, this protein may act as a trigger for parturition.
, corticotropin releasing factor
, corticotropin-releasing factor
, corticotropin-releasing hormone
, corticotropin releasing hormone
, corticotrophin-releasing factor
, corticotropin releasing hormone, gene 1
, corticotropin-releasing factor b
, corticotropin releasing hormone b
, Corticotropin-releasing hormone
, corticotropin releasing hormone a
, corticotropin-releasing factor a